XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.3
REVENUE
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Screening
Medicare Parts B & C$173,624 $140,366 $521,370 $389,373 
Commercial253,401 188,923 732,182 531,789 
Other44,988 31,470 124,443 100,013 
Total Screening472,013 360,759 1,377,995 1,021,175 
Precision Oncology
Medicare Parts B & C$46,383 $47,038 $141,352 $152,224 
Commercial44,430 42,660 135,574 134,658 
International38,599 31,533 111,453 89,536 
Other26,913 30,212 80,552 81,640 
Total Precision Oncology156,325 151,443 468,931 458,058 
COVID-19 Testing$— $10,871 $5,955 $52,051 
Total$628,338 $523,073 $1,852,881 $1,531,284 
Screening revenue primarily includes laboratory service revenue from Cologuard and Prevention Genetics, LLC (“PreventionGenetics”) tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $4.7 million and $6.4 million for the three months ended September 30, 2023 and 2022, respectively. The Company recognized revenue from a change in transaction price of $23.7 million and $17.6 million for the nine months ended September 30, 2023 and 2022, respectively.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not material as of September 30, 2023 and December 31, 2022.
Revenue recognized for the three and nine months ended September 30, 2023 and 2022 that was included in the deferred revenue balance at the beginning of the period was not material.